Repatha evolocumab regulatory update

Japan approved Repatha evolocumab from Amgen to treat familial hypercholesterolemia and hypercholesterolemia in patients who have a high risk of cardiovascular events and do not adequately respond to statins. The company said Repatha is the first PCSK9 inhibitor approved in Japan. Amgen said Repatha will be available in Japan as soon as the government determines the drug’s National Health Insurance price. ...